New Data Show TREMFYA® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
In vitro research counsel TREMFYA neutralizes IL-23 the place it's produced, enhancing the power of TREMFYA to stop native activation ...
